Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.
Metastatic colorectal cancer patients whose tumors harbor mutations in KRAS (and to a lesser extent, in BRAF) are unlikely to respond to costly anti-EGFR therapies. Screening of patients who are candidates for these therapies for mutations in one of these genes (KRAS) has been recommended, with the goal of providing treatment to those who are likely to benefit from it while avoiding unnecessary costs and harm to those who are not likely to benefit. However, the real-world impact of mutation screening for both KRAS and BRAF is unclear.
To better understand the impact of mutation screening with regard to health outcomes, costs, and value, Ajay S. Behl, Ph.D., M.B.A., of the HealthPartners Research Foundation in Bloomington, Minnesota, and colleagues, performed a cost-effectiveness analysis that took into account the treatments, resection of metastases, and survival for the different types of metastases. They conducted patient-level decision analytic simulation modeling comparing four strategies involving KRAS and BRAF mutation testing to select treatments for metastatic colorectal cancer patients: no anti-EGFR therapy (best supportive care); anti-EGFR therapy without screening; screening for KRAS mutations only (before providing anti-EGFR therapy); and screening for KRAS and BRAF mutations (before providing anti-EGFR therapy).
The researchers found that compared with no anti-EGFR therapy, screening for both KRAS and BRAF mutations showed a very high (ie, unfavorable) incremental cost-effectiveness ratio, meaning it was very costly in relation to its benefits. Compared with anti-EGFR therapy without screening, screening for KRAS mutations saved approximately $7,500 per patient; adding BRAF mutation screening saved another $1023, with little reduction in expected survival.
The authors write, "In general, our results are less supportive of the use of anti-EGFR therapy than previous analyses, and they indicate lower cost savings from KRAS testing than previously reported. Although we cannot confirm that anti-EGFR therapy is a cost-effective use of health care resources, we can affirm that KRAS testing is cost-saving. BRAF testing may offer additional savings."
In an accompanying editorial, Josh J. Carlson, M.P.H., Ph.D., of the Department of Pharmacy, University of Washington, and Scott D. Ramsey, MD, PhD, of the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, both in Seattle, note two practical points highlighted by the study: that molecular testing is as much about generating cost savings by identifying nonresponders as it is about improving survival by identifying responders, and that good modeling must account for the fact that community practice (as opposed to clinical trials) "is messy." They write, "most importantly, this study of an unusually accurate test raises important issues that should be considered for other molecular tests in other settings."
Journal of the National Cancer Institute: http://jncicancerspectrum.oupjournals.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A wild male marmoset is filmed embracing and caring for his dying female partner.
A neuroscientist and a musician explain how they built the Brain Stethoscope, which is both brain scanner and musical instrument
Museum staff will ditch the bubble wrap in favor of custom-molded plaster cradles when shipping a Tyrannosaurus rex to Washington, D.C.
The direction you're moving can play tricks with your mind. That can mean trouble not only for travel but for human relations too
In Missing Microbes, Dr. Martin Blaser argues that the overuse of antibiotics, as well as now-common practices like C-sections, may be messing with gut microbes.
Scientists have figured out one reason women might be more vulnerable to Alzheimer's: A risk gene doubles women's chances of getting the disease but has minimal effect on men.
Harvestmen (also known as daddy long legs) aren’t spiders, and if you could (or wanted to) lean close enough, you’d be able to see one of the few physical features that distinguish them from their arachnid cousins. It’s in the eyes: Spiders usually have 6 or more, but the harvestman has only one set, tightly […]
Cuttlefish are far and away nature’s most adept camouflagers, capable of observing their surroundings and perfectly adjusting not only their color but also their skin texture in just 250 milliseconds. And it’s not just about blending in: They can also launch truly bizarre displays of rippling colors to either intimidate rivals or hypnotize prey. Oh, also. They’re color blind. Yeah … scientists aren’t quite sure how that’s possible quite yet.
Virtual records of fragile archaeological sites will preserve them for future generations when it's not possible to defend them from the elements
Holy Da Vinci Code! Chemical and epigraphic analyses suggest the "Gospel of Jesus's Wife" could be real.